Michele Mercuri

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

Robert P. Giugliano, Christian T. Ruff, Eugene Braunwald et al. · New England Journal of Medicine · 2013 · 5.1K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

Gary E. Raskob, Nick van Es, Peter Verhamme et al. · New England Journal of Medicine · 2017 · 1.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

Cynthia J. Girman, Thomas Rhodes, Michele Mercuri et al. · The American Journal of Cardiology · 2004 · 531 citations

Medicine, Cardiology, Preventive Medicine +16

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

Christian T. Ruff, Robert P. Giugliano, Elliott M. Antman et al. · American Heart Journal · 2010 · 482 citations

Medicine, Cardiology, Pharmacology +14

Effects of Lipid-Lowering by Simvastatin on Human Atherosclerotic Lesions

Roberto Corti, Zahi A. Fayad, Valentı́n Fuster et al. · Circulation · 2001 · 478 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +15